Fed. Circ. Partially Revives Amgen's Sensipar Patent Fight
The Federal Circuit on Tuesday gave Amgen another chance to prove Amneal infringed a patent covering its blockbuckser product Sensipar with a planned generic version of the drug given to patients...To view the full article, register now.
Already a subscriber? Click here to view full article